When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the […]
In my series eight simple reasons to pause before getting an unlicensed stem cell treatment from a non-compliant clinic I have covered the first five: (1) potential loss of insurance coverage for negative outcomes that could cost hundreds of thousands of dollars, (2) failure of patient follow up by the doctors and clinics, (3) exclusion from future clinical trial
I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As
Interviews with leaders and top players in the stem cell field Read More »
CIRM recently held an “elevator pitch” (also sometimes known as an “elevator speech”) contest amongst its grantees. The San Francisco Chronicle even covered this contest (and also here). Kevin McCormack, Sr. Director of Public Communications and Patient Advocate Outreach at CIRM, described the contest in, appropriately enough, a speech. As best as I can tell 56 scientists participated. By way
My top 3 favorite CIRM elevator pitches Read More »
Would you want a GI specialist doing your heart surgery? How about a radiologist doing your brain surgery? I wouldn’t. So why then do so many patients accept that the doctor doing their stem cell transplant has no training in that area? I’m doing a series on eight simple reasons not to get an unlicensed
A few days ago I had a long, very enjoyable phone conversation with the father of the mesenchymal stem cells (MSC) field, Dr. Arnold Caplan. Dr. Caplan is Professor of Biology, Director Skeletal Research Center at Case Western. He coined the phrase “mesenchymal stem cell” in the late 1980s. I’m going to break the interview
Insightful interview with Arnold Caplan: Part 1: MSC history, nomenclature, & properties Read More »
What can a giant goldfish teach stem cell researchers about clinical use of the cells? It turns out, a great deal! A few weeks ago researchers from my home institution UC Davis and the US Forest Service made headlines with reported catches of giant goldfish in Lake Tahoe. These are not your grandad’s pond’s “big”
Giant goldfish teach researchers about stem cell treatments Read More »
Last night there was a great fund-raising event for the St. Baldrick’s Foundation for children’s cancer research here in Sacramento. I was honored to captain the UC Davis School of Medicine Team (see at left). So far we have raised almost $2,500 for St. Baldrick’s. Please consider pitching in via this link. You can help
Bald heads & big smiles: St. Baldrick’s 2013 Sac Event Inspires Read More »
Allan Robins of Viacyte (pictured at left–sorry for the fuzzy image) and Paul Simmons of Mesoblast presented this morning at the CIRM Grantee Meeting. Both talks were outstanding. Robins went first. He started by saying how Viacyte had a productive pre-IND meeting with the FDA last year. I believe a target for them is to
Viacyte & Mesoblast present at CIRM Meeting Read More »
How do dubious stem cell clinics get patients in the door to make money? In part they do this via the Internet via the clinics’ own websites. There are also patient websites, some secret, which may serve ad recruitment tools for specific clinics. A more general tactic may be the use of so-called “recruiter-patients”. There
Recruiter-patients: how common & corrupt is this practice at US stem cell clinics? Read More »